Zai Lab Limited ZLAB
Regular-session close
After hours · Nov 19, 4:42 PM ET
- YTD
- +24.26%
- 1 year
- +6.93%
5D -3.54 (-13.39%)
- Market cap
- 2.74B
- Revenue (ttm)
- 441.73M
- Profit margin
- -44.91%
- EPS (ttm)
- -1.80
- Shares out
- 124.84M
- Forward P/E
- -10.92
- YTD return
- +24.26%
- 1-year return
- +6.93%
- 50-day average
- 24.46
- 200-day average
- 21.40
- Volume
- 611.42K
- Avg volume
- 996.56K
- Open
- 21.94
- Previous close
- 22.11
- Day's range
- 21.70 – 22.27
- 52-week range
- 15.96 – 29.02
- Beta
- 0.72
- Analysts
- Strong Buy
- Price target
- 34.21 (+56.1%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 2.19B
- Price / sales
- 6.20
- Price / book
- 4.38
- Revenue growth
- -6.80%
- Free cash flow
- -120.17M
- Total cash
- 559.66M
- Total debt
- 267.45M
- Return on equity
- -29.99%
- Short % of float
- 6.64%
Fundamental scorecard
8 of 25 checks passed on ZLAB’s reported financials
8of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 24.25
- Target (mean)
- 34.21
- Target (high)
- 56.00
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.54968.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.53895 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.59177 | -0.41 | +0.18 | +30.72% |
| Aug 6, 2026 | Jun 30, 2026 | -0.67939 | -0.46 | +0.22 | +32.29% |
| May 7, 2026 | Mar 31, 2026 | -0.52616 | -0.46 | +0.07 | +12.57% |
| Feb 26, 2026 | Dec 31, 2025 | -0.44 | -0.46 | -0.02 | -4.55% |
| Nov 6, 2025 | Sep 30, 2025 | -0.28 | -0.33 | -0.05 | -17.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Citigroup | main | Buy | Buy |
| May 8, 2026 | Citigroup | main | Buy | Buy |
| Mar 18, 2026 | JP Morgan | main | Overweight | Overweight |
| Feb 27, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Feb 5, 2026 | JP Morgan | main | Overweight | Overweight |
| Jan 7, 2026 | UBS | init | — | Buy |
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- zailaboratory.com
News
JP Morgan Maintains Overweight on Zai Lab, Raises Price Target to $37
Zai Lab: The China Engine Pays The Bills, Zoci Could Pay The Upside (Initiating Buy)
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Zai Lab Announces Participation in Investor Conferences in November 2026
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium
Your note
Sign in to keep a note on ZLAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMADO RAFAEL | President | Sale | Apr 5, 2026 | 57,022 |
| DIEKMAN JOHN DAVID | Director | Stock Award(Grant) | Jun 16, 2026 | 122,140 |
| DU YING SAMANTHA | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2026 | 1,221,400 |
| GAYNOR RICHARD BRIAN M.D. | Director | Purchase | Nov 9, 2026 | 81,965 |
| LEUNG NISA BERNICE WING-YU | Director | Stock Award(Grant) | Jun 16, 2026 | 96,297 |
| MOULDER LEON OLIVER JR. | Director | Stock Award(Grant) | Jun 16, 2026 | 94,973 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 8.27% | 10,350,973 | 226.89M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 4.98% | 6,229,081 | 136.54M | Sep 29, 2026 |
| Woodline Partners LP | 4.24% | 5,299,113 | 116.16M | Sep 29, 2026 |
| Adar1 Capital Management, LLC | 2.70% | 3,381,364 | 74.12M | Sep 29, 2026 |
| RA Capital Management, L.P. | 2.25% | 2,815,543 | 61.72M | Sep 29, 2026 |
| Goldman Sachs Group Inc | 1.53% | 1,912,532 | 41.92M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BARON SELECT FUNDS-Baron Emerging Markets Fund | 1.10% | 1,370,904 | 30.05M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.59% | 740,494 | 16.23M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.27% | 331,780 | 7.27M | Sep 29, 2026 |
| abrdn World Healthcare Fund | 0.25% | 311,294 | 6.82M | Jun 29, 2026 |
| Tema ETF Trust-Tema Oncology ETF | 0.13% | 161,278 | 3.54M | Aug 30, 2026 |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 0.11% | 134,267 | 2.94M | Aug 30, 2026 |
